Value of cardiac rehabilitation Prof. Dr. L Vanhees
|
|
- Jeffery Watts
- 5 years ago
- Views:
Transcription
1 Session: At the interface of hypertension and coronary heart disease haemodynamics, heart and hypertension Value of cardiac rehabilitation Prof. Dr. L Vanhees ESC Stockholm August 2010
2 Introduction There is a strong and frequent association between arterial hypertension (HT) and coronary heart disease (CHD): Magnitude of HT has an impact on the incidence of CHD: i.e. there is a direct, strong, independent and continuous relation between BP and cardiovascular mortality and morbidity and this from 115/75 mmhg on 1. CHD is primary cause of mortality in hypertensive patients 25-43% of patients in secondary prevention trials have HT (CARE, LIPID, 4S) 2 Mortality rate of CHD is 2.3 times greater when HT is present 1 1 Lewington et al. Lancet Escobar E. J Hum Hypertens 2002
3 Treatment of hypertension General principles for the treatment of hypertension fully apply to patients with CHD and HT. However, treatment of hypertension in patients with CHD must be more aggressive than in the absence of CHD. Risk of a recurrent coronary event in this population is very high and all efforts should be expended in order to lower BP Reducing BP is cornerstone of strategies to reduce the number of fatal and no-fatal cardiovascular events both in patients with or withhout CHD Focus on CR and Exercise Training in this talk
4 Joint Associations of Physical Activity and Aerobic Fitness on the Development of Incident Hypertension Coronary Artery Risk Development in Young Adults An inverse, graded association between fitness category and the development of hypertension Carnethon M.R. et al., Hypertension. 2010
5 Joint Associations of Physical Activity and Aerobic Fitness on the Development of Incident Hypertension Coronary Artery Risk Development in Young Adults Carnethon M.R. et al., Hypertension. 2010
6 Kokkinos et al. Hypertension 2009; 53: Role of Physical Fitness: HT, PF and Mortality
7 Exercise Capacity and Mortality in Hypertensive Men With and Without Additional Risk Factors Kokkinos P. et al., Hypertension;2009
8 Kokkinos et al. Am J Hypertens 2009; 22: Role of Physical Fitness: Pre-HT, PF and Mortality
9 Exercise Capacity and All-Cause Mortality in Prehypertensive Men Cumulative survival for entire cohort Kokkinos P. et al., Am J Hypertens. 2009
10 Exercise Capacity and All-Cause Mortality in Prehypertensive Men Cumulative survival for individuals 60 years of age Cumulative survival for individuals >60 years of age -> A strong, inverse and graded association between exercise capacity and all-cause mortality. -> More protective effects of increased fitness in younger individuals age should be more closely considered when assessing fitness and mortality relationships. Kokkinos P. et al., Am J Hypertens. 2009
11 Role of Physical fitness CHD, PF and mortality 6213 men referred for ET Mean FU: 6.2 ±3.7 yrs Two groups: Normal subjects with normal test and no CV history Subjects with abnormal test and/or history of CV disease End-point: overall mortality Myers J et al. NEJM 2002; 346:
12 Role of Physical fitness CHD, PF and mortality 6213 men referred for ET Mean FU: 6.2 ±3.7 yrs Two groups: Normal subjects with normal test and no CV history Subjects with abnormal test and/or history of CV disease End-point: overall mortality Normal subjects Myers J et al. NEJM 2002; 346:
13 Role of Physical fitness CHD, PF and mortality 6213 men referred for ET Mean FU: 6.2 ±3.7 yrs Two groups: Normal subjects with normal test and no CV history Subjects with abnormal test and/or history of CV disease End-point: overall mortality Years of Follow-up Patiënts with Heart Disease Myers J et al. NEJM 2002; 346:
14 Role of Physical fitness CHD, PF and mortality rehabilitation candidates (CABG, MI, IHD that completed an exercise test Median FU: 7.9 yrs (4-29 yrs) End-point: all-cause and cardiac mortality 15 yr survival rates for peakvo 2 of <15, 15 to 22, and > 22ml/min/kg were 65%, 81% and 88%. when treated as a continuous variable, a 1ml/min/kg increments in peakvo 2 could be equated with a 9% improvement in prognosis Kavanagh et al. Circulation 2002; 106:
15 Definition Cardiac Rehabilitation Sum of activity and interventions required to ensure the best possible physical, mental and social conditions so that patients with chronic or post-acute cardiovascular disease may, by their own efforts, preserve or resume their proper place in society and lead an active life 1 How: programme of prescribed exercise and interventions designed to modify coronary risk factors with the use of optimised drug therapy and appropriate lifestyle changes. Exercise therapy is a central element in CR as identified by international clinical guidelines. 1 World Health Organ Tech Rep Ser 1993; 831:
16 Endurance Exercise and Hypertension Number of studies 72 (study groups: 105; 28 optimal pressure, 46 prehypertension; 31 hypertension) Number of participants: randomized: (median: 32; range: 8-357) analysed: (overall: 88.7%; range: ) Demographic characteristics gender: ~ 57% male Age: median 46.6 yrs (range: 21-83) Cornelissen VA and Fagard RH, Hypertension 2005; 46:
17 Endurance Exercise and Hypertension Duration (weeks): 16 (4-52) Frequency (n/week): 3 (1-7) Intensity (%HRres): 65 ( ) Duration/session (min)*: 40 (15-63) Mode: predominantly walking, jogging, running or cycling Values are median (range) *without warming-up and cool-down Increase in peakvo ml/min/kg (95% CL: 3.5 to 4.5) Cornelissen VA and Fagard RH, Hypertension 2005; 46:
18 Endurance Exercise and Hypertension effect on BP Training frequency, intensity, duration and mode are not significantly related to the BP response to training Cornelissen VA and Fagard RH, Hypertension 2005; 46:
19 Endurance Exercise and Hypertension Effect on Hemodynamics Cornelissen VA and Fagard RH, Hypertension 2005; 46:
20 Resistance Exercise and BP Number of studies (RCTs): 25 Number of study groups: 30 (optimal pressure: 12; prehypertension: 14; hypertension: 4) Number of participants: randomized: 961 (median 30, range ) analysed: 860 (overall 91% range %) Demographic characteristics gender: median 28% men (range 0-100) Mean age: median 53 yrs (range yrs) V. Cornelissen, R. Fagard, L. Vanhees. Unpublished data
21 Resistance Exercise and BP Variable N studies Median Range Duration (wks) Frequency (times/wk) Intensity (% 1RM) Exercises (#) Sets (#/exercise) Repetitions/set (#) Progressive 26 Supervised 23 Significant increase in peak VO 2 = 2.7 ml/min/kg (0.81 to 4.56)
22 CCornelissen et al. Unpublished data Resistance Exercise and BP: SBP weighted for the inverse of the variance
23 Resistance Exercise and BP: SBP weighted for the n of trained participants CCornelissen et al. Unpublished data
24 Resistance Exercise and BP: DBP weighted for the inverse of the variance CCornelissen et al. Unpublished data
25 Resistance Exercise and BP: DBP weighted for the n of trained participants CCornelissen et al. Unpublished data
26 Resistance Exercise and BP Variable N Net change (95% CL) I² SBP (mmhg) - normotension (-4.98; -0.70) 37 - hypertension (-5.48; +2.02) 0 DBP (mmhg) -normotension (-4.65; -1.93) 22 - hypertension (-3.13; +0.91) 0 CCornelissen et al. Unpublished data
27 Resistance exercise and BP: role of training intensity Changes in SBP and DBP, adjusted for control data, versus training intensity (% 1RM) for 26 study groups that reported data. The weighted meta-regression coefficients are r=0.048 (P=0.82) for SBP and r=0.12 (P=0.57) for DBP. CCornelissen et al. Unpublished data
28 Number of patients Distribution of changes in peak VO 2 (%) after Cardiac Rehabilitation Change in peak oxyen uptake (% ) Vanhees et al, Eur J Cardiovasc Prevention Rehab, 2004.
29 Probability for cardiovascular mortality (%) Probability for cardiovascular mortality (%) Exercise capacity and it s change by ET on CV mortality Mean Plus 95 % CL Min 95 % CL Mean Plus 95 % CL Min 95 % CL Peak Oxygen Uptake (ml/min/kg) Delta Peak Oxygen Uptake (ml/min) L. Vanhees et al. JACC, 1994 L. Vanhees et al. Am J Cardiol 1995
30 Value of Cardiac Rehabilitation: CHD effect on total mortality Meta-analyses of randomized controlled trials which assessed the effects of exercise training alone or in combination with psychological or eductional interventions: Oldridge (1988), Jolliffe et al (2001) and Taylor et al (2004) trials patients with CHD Taylor et al. Am J Med 2004; 116:
31 Effect on Total Mortality 0.80 (0.68; 0.93) Taylor et al. Am J Med 2004; 116:
32 Value of Cardiac Rehabilitation: CHD effect on cardiac mortality 0.74 (0.61; 0.90) Taylor et al. Am J Med 2004; 116:
33 Value of Cardiac Rehabilitation: CHD effect on BP Taylor et al. Am J Med 2004; 116:
34 Aim: Value of Cardiac Rehabilitation: CHD and Hypertension to investigate whether the effect of cardiac rehabilitation differs between CHD patients with and without HT Study population: patients with a diagnosis of acute myocardial infarction, CABG, PCI or patients with chronic angina who were referred to our CR unit and completed an exercise test at baseline and following 3 months of CR. Cardiac Rehabilitation Programme: - Optimal medical treatment - Risk factor management - Nutritional counseling - Psychosocial management - Exercise therapy Own data; unpublished
35 Value of Cardiac Rehabilitation: CHD and hypertension Exercise intervention: supervised Mode: endurance training (cycling, running, arm ergometry, rowing, dynamic calisthenics) followed by relaxation Duration: approximately 100 minutes/session Frequency: on average 2.27 (SD 0.47) exercise sessions weekly during 3 months Intensity: 80.7 ±19.6 % HRpeak Own data; unpublished
36 Patient Characteristics CHD without HT CHD with HT N of patients 1688 (71%) 704 (29%) Men n (%) 1576 (93%) 622 (88%) Age (years) 55.8± ±9 * Drug therapy -Beta-blockers -Antiplatelets -ACE-inhibitors -AII-antagonists -diuretics -Ca- antagonists -other vasodilators 1345 (80%) 1277 (76%) 297 (17.6%) 9 (0.53%) 77 (4.5%) 185 (11%) 328 (19.4) 590 (84%)* 553 (79%) 181 (26%)* 14 (2%)* 63 (9%)* 116 (16%)* 167 (24%)* *, <0.05 Own data; unpublished
37 Baseline Characteristics CHD without HT CHD with HT P-value Weight (kg) 75.9± ±11.9 <0.001 BMI (kg/m²) 25.5± ±3.5 <0.001 Ejection Fraction 59.0± ±15.4 NS HRrest (bpm) 67.2± ±12.2 NS SBPrest (mmhg) 127.6± ±19.7 <0.001 DBP rest (mmhg) 76.8± ±12.9 <0.001 VO 2 peak (ml/min) 1720± ±474.7 <0.001 Oxygen pulse (ml/beat) 13.4± ±3.2 <0.001 HRpeak (bpm) 129.4± ±20.9 <0.001 RER 1.13± ±0.12 NS EqO2 37.3± ± 7.1 NS Own data; unpublished
38 Results: exercise capacity Own data; unpublished
39 Results: exercise capacity * P<0.001 within group Own data; unpublished
40 Results: exercise capacity * P<0.001 within group Own data; unpublished
41 Results: other characteristics Absolute Change Relative Change (%) CHD CAHD with HT CHD CHD with HT Oxygen pulse (ml/beat) +2.0±2.19** 2.30±6.26** ±19.7** 20.83±20.51** HRpeak (bpm) +8.43±15.86** +7.51±14.76** +7.69±14.13** 6.78±12.42** HRrest (bpm) -2.29±10.69** -3.42±10.66**$ -2.11±15.6** -3.82±14.72**$ SBPrest (mmhg) -0.95±16.36* -2.91±19.29**$ +0.11± ±14.05*$ DBPrest (mmhg) -1.04±10.12** -1.98±10.91**$ -0.37± ±13.82* Data are expressed as mean + SD. * P< 0.05; **P<0.001 for within group changes; $ P<0.05 for between group changes Own data; unpublished
42 Conclusions There is a dose-response relation between physical fitness and all-cause and cardiac mortality in both hypertensive patients and CHD patients with and without HT Both endurance and dynamic resistance training result in a significant increase in peakvo 2 and induce a significant reduction in SBP and DBP. CR including exercise results in a significant larger reduction in all-cause and cardiac mortality and a greater reduction in BP, although only significant for SBP. In CHD patients with HT, CR induces a significant larger reduction in SBP and HR compared to patients without HT. No differences could be observed with regard to the effect on peak VO 2
The role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationHigh Intensity Interval Exercise Training in Cardiac Rehabilitation
High Intensity Interval Exercise Training in Cardiac Rehabilitation Prof. Leonard S.W. Li Hon. Clinical Professor, Department of Medicine, The University of Hong Kong Director, Rehabilitation Virtus Medical
More informationClinical Considerations of High Intensity Interval Training (HIIT)
Clinical Considerations of High Intensity Interval Training (HIIT) Jenna Taylor Exercise Physiologist & Dietitian The Wesley Hospital PhD Candidate The University of Queensland What is High Intensity Interval
More informationEffects of exercise, diet and their combination on blood pressure
(2005) 19, S20 S24 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effects of exercise, diet and their combination on blood pressure Department
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationThe importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher
The importance of follow-up after a cardiac event: CARDIAC REHABILITATION Dr. Guy Letcher The National Medicare Experience Mortality After Angioplasty 225,915 patients Mortality After Bypass Surgery 357,885
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationReliability of the incremental shuttle walk test and the Chester step test in cardiac rehabilitation
Reliability of the incremental shuttle walk test and the Chester step test in cardiac rehabilitation Item Type Thesis or dissertation Authors Reardon, Melanie Publisher University of Chester Download date
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHigh intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes
High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes Sophie Cassidy, s.cassidy@ncl.ac.uk 1) Concentric remodelling 1.2 * Eccentricity ratio
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationPHYSICAL AND SEXUAL ACTIVITIES
Forgotten problems in HF PHYSICAL AND SEXUAL ACTIVITIES Massimo F Piepoli, MD, PhD, FESC, FACC Heart Failure Unit, Guglielmo da Saliceto Hospital, Piacenza m.piepoli@alice.it No disclosures Massimo Speaker
More informationCardiac Rehabilitation after Primary Coronary Intervention CONTRA
DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationCardiac rehabilitation: a beneficial effect in CHD?
Cardiac rehabilitation: a beneficial effect in CHD? An Van Berendoncks Department of Cardiology Antwerp University Hospital Outline Why exercise training in CHD? Risk and benefits? Feasibility? Why should
More informationRebuilding and Reinvigorating Cardiac Rehabilitation in 2018
Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health
More informationExercise Training: The Foundation of
Exercise Training: The Foundation of Cardiac Rehabilitation 6th Korean Cardiopulmonary Rehabilitation Workshop 2012 Philip A. Ades MD University of Vermont College of Medicine Burlington, Vermont, USA
More informationValue of Cardiac Rehabilitation for Improving Patient Outcomes
Value of Cardiac Rehabilitation for Improving Patient Outcomes Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationCardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System
Cardiac Rehabilitation for Heart Failure Patients Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Disclosures There are no conflict of interests related to this presentation.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationHYPERTENSION AND HEART FAILURE
HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationPRESENTED BY BECKY BLAAUW OCT 2011
PRESENTED BY BECKY BLAAUW OCT 2011 Introduction In 1990 top 5 causes of death and disease around the world: Lower Respiratory Tract Infections Diarrhea Conditions arising during pregnancy Major Depression
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCardiac Rehabilitation The Evidence Base & Implications for Practice
Cardiac Rehabilitation The Evidence Base & Implications for Practice Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham Bisperbjerg Hospital, Copenhagen 11 th & 12 th December
More informationMean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014
Mean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014 CVD Event Rates Major CVD = death from CV causes, stroke, MI and HF Non major CVD = all other CVD events that led to hospitalization Yusuf et al
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationApproach to CPET. CPET Cases. Case 1 4/4/2018. Impaired? Cardiac factors? Ventilatory factors?
Approach to CPET CPET Cases Neil MacIntyre MD Duke University Medical Center Durham NC Impaired? Work,, /kg Cardiac factors?, /, BP, Rhythm Ventilatory factors? Ve/MVV (incl EIB, trapping), PaCO2 Gas exchange
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationScope
Scope Global burden of heart disease Physical activity trends Overview of CR A happy problem Principles of CR in athletes Classification of sport Existing guidelines Exercise testing & prescription HIIT
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationBenefits of Combined Aerobic/Resistance/Inspiratory Muscle Training in Patients with Chronic Heart Failure. The Ideal Exercise Program for CHF?
Benefits of Combined Aerobic/Resistance/Inspiratory Muscle Training in Patients with Chronic Heart Failure. The Ideal Exercise Program for CHF? I D. Laoutaris, S Adamopoulos, A Manginas, D B. Panagiotakos,
More informationSubject: Outpatient Phase Ii Cardiac Rehab Individualized Treatment Plan And Exercise Prescription
CARDIAC REHAB POLICY & PROCEDURES Policy #: CR 208 Subject: Outpatient Phase Ii Cardiac Rehab Individualized Treatment Plan And Exercise Prescription Purpose: To establish guidelines for developing and
More informationExercise after CABG: The Good The Bad and the Ugly
Exercise after CABG: The Good The Bad and the Ugly Ph Meurin. Les Grands Prés (Villeneuve Saint Denis) No conflict of Interest After CABG, the Prognosis is Good.. Age 65 ± 10 Male Gender 80 % Pre-op LVEF
More informationGastrocnemius, see Medial gastrocnemius Glucose, see Blood glucose
Subject Index Acute myocardial infarction, see Myocardial infarction Aerobic capacity cardiac patients and Tai Chi training effects 185 heart failure and Tai Chi outcomes 198 200, 202, 205 meta-analysis
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationThe Art and Science of Exercise Prescription in Patients with Cardiovascular Disease
The Art and Science of Exercise Prescription in Patients with Cardiovascular Disease Prescribe Exercise FITT Principle Frequency Intensity Time or duration Type or modality Exercise Prescription with or
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationThe life after myocardial infarction: a long quiet river?
The life after myocardial infarction: a long quiet river? Cardiac rehabilitation: for whom and how? Dr. Barnabas GELLEN MD, PhD, FESC Poitiers JESFC 2018 - Paris Conflicts of interest Speaker honoraria
More informationPopular ball games: football, tennis, golf
ESC Congress 2011 Paris, August 29 th Clinical Seminar: How to advise patients about resuming sports activity Popular ball games: football, tennis, golf Tim Meyer (no conflict of interest) Institute of
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationCardiac Rehabilitation Program for LVAD Patients. Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR
Cardiac Rehabilitation Program for LVAD Patients Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR Left Ventricular Assist Devices (LVAD) Improved Survival Following LVAD Implantations
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationKhai Pham Gia. Vietnam Cardiovascular Organization Cardiovascular Hospital. Hanoi, Vietnam. Declared no potential conflict of interest.
Khai Pham Gia Vietnam Cardiovascular Organization Cardiovascular Hospital Hanoi University of Medicine Hanoi, Vietnam Declared no potential conflict of interest. Hypertension in Patients with Coronary
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationHF-PEF: Symptoms, quality of life and mortality/morbidity
HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationSet foundation for exercise prescription Clarify the work rest relationship Understand VO2M Understand overtraining Look at how to use aerobic
Set foundation for exercise prescription Clarify the work rest relationship Understand VO2M Understand overtraining Look at how to use aerobic equipment Specific, Measurable, Action-oriented, Realistic,
More informationTable 5: Metabolism after Prolonged High-Intensity Intermittent or Sprint Interval Training
Table 5: Metabolism after Prolonged High-Intensity Intermittent or Sprint Interval Training 54 8 adults (sex n.r.), type 2 diabetes, 63±8 years, BMI 32±6, VO2peak n.r. HIIT: 10 x 1 min intervals at ~90%
More informationImproved control for confounding using propensity scores and instrumental variables?
Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationCARDIAC REHABILITATION
CARDIAC REHABILITATION A N A B A R A C M D, P H D M E D S T A R H E A R T A N D V A S C U L A R I N S T I T U T E, M E D S T A R W A S H I N G T O N H O S P I T A L C E N T E R OBJECTIVES Rationale for
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationSECONDARY HYPERTENSION
HYPERTENSION Hypertension is the clinical term used to describe a high blood pressure of 140/90 mmhg or higher (National Institute of Health 1997). It is such a health risk the World Health Organisation
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationThe Role of Cardiac Rehabilitation in Recovery & Secondary Prevention. Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager
The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager Objectives Core Components of Cardiac Rehab Program CR Indications &
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More informationPrimary Physiological
Appendix Table 3. Primary outcomes and effect sizes for trials included in review. Trial Behavior Outcome Effect size Group difference in original units Primary Physiological ACT 22, a Be Fit, Be Well
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationHEART FAILURE AN OMINOUS DISEASE
HEART FAILURE AN OMINOUS DISEASE Conflicts of Interest I Have No Conflicts of Interest to Disclose Objective At the conclusion of this presentation, the participants will be able to identify benefits and
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationAssociate Professor Gerry Devlin
Associate Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton 9:00-9:15 Secondary Prevention of IHD The Challenge of Secondary Prevention Associate
More informationExercise and Hypertension
SPECIAL COMMUNICATIONS POSITION STAND Exercise and Hypertension This pronouncement was written for the American College of Sports Medicine by Linda S. Pescatello, Ph.D., FACSM, (Co-Chair), Barry A. Franklin,
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationThe U.S. Surgeon General recommended in
Moderate- or Vigorous-Intensity Exercise: What Should We Prescribe? by David P. Swain, Ph.D., FACSM Learning Objectives To understand the potential value of vigorous-intensity exercise in the prevention
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationThe magnitude and duration of ambulatory blood pressure reduction following acute exercise
Journal of Human Hypertension (1999) 13, 361 366 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE The magnitude and duration of ambulatory
More information